← Russell 3000 cross-section

VYGR Voyager Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$212m
Revenue TTM
$34m
Net income TTM
$-108m
Free cash flow
$-121m
Composite score
29.4
Sector rank
#2845

Valuation

P / E
EV / EBITDA
EV / sales
2.8
FCF yield
-57.37%
Earnings yield vs 10-yr
-55.61pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-312.6%
EBITDA margin
-329.0%
ROE
-69.8%
ROIC
-308.1%
Revenue growth
-19.1%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We are also eligible to receive (a) specified sales milestone payments of up to an aggregate of $400.0 million for the Novartis SMA Program and up to an aggregate of $375.0 million for the Novartis HD Program and (b) tiered, escalating royalties in the high single-digit to low double-digit percentages of annual net sales of the Novartis SMA Program Products and the Novartis HD Program Products. We are eligible to receive (a) specified sales milestone payments of up to an aggregate of $175.0 million per Novartis Licensed Product directed to the remaining Initial Novartis Target and (b) tiered, escalating royalties in the mid-to high-single-digit percentages based on annual net sales of each N …Voyager Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →